시장보고서

상품코드

1908227

종양학 분야 AI 시장 규모, 점유율, 동향 분석 보고서 : 구성요소 유형별, 암 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

AI In Oncology Market Size, Share & Trends Analysis Report By Component Type, By Cancer Type, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033

발행일: 2025년 12월 | 리서치사:

Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

종양학 분야 AI 시장 개요

세계의 종양학 분야 AI 시장 규모는 2025년에 60억 달러로 추정되며, 2033년에 389억 1,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 사이에는 CAGR 24.77%로 성장할 것으로 예상됩니다. 암 발병률 증가, 암 진단 기술 및 의료 인프라의 발전, 암의 조기 발견 및 분류에 대한 수요 증가에 따른 시장 성장에 기인합니다.

또한, 정밀의료의 도입 확대가 시장 성장을 더욱 촉진하고 있습니다. 전 세계적으로 암 발생률이 증가함에 따라 종양학 분야에서 AI에 대한 의존도가 높아지고 있습니다. 미국 국립보건원(NIH)의 2023년 추정에 따르면, 미국에서는 약 200만 명이 암 진단을 받았다고 합니다. 유방암은 가장 많이 진단된 암으로 여성은 약 29만 7,790명, 남성은 2,800명으로 보고되고 있습니다. 남성의 경우 전립선암은 가장 빈번하게 진단되는 암이며, 전체적으로는 두 번째로 많이 진단되는 암으로 약 28만 8,300여 건으로 추정됩니다. 폐암과 기관지암의 신규 확진자 수는 추정치 기준 세 번째로 많은 것으로 나타났습니다.

공공 및 민간 기관의 연구개발(R&D) 투자 확대, 특히 새로운 기술 도입을 위한 노력의 증가는 시장의 성장을 더욱 촉진할 것으로 예상됩니다. 예를 들어, 2022년 10월 정밀의료 및 AI 전문 기업 템퍼스는 '템퍼스 플러스(Tempus Plus)' 프로그램을 발표했습니다. 이 독자적인 프로그램은 실제 데이터를 활용하여 공동 정밀 종양학 연구를 촉진하는 프로그램입니다. 베일러 의대, Allegheny Health Network, Stanford Cancer Center, Rush University Medical Center, TriHealth 등의 연구자 커뮤니티는 이미 연구 추진을 위해 Tempus+ 프로그램을 활용하고 있습니다. 또한, AI 관련 의료기기의 제품 승인 증가가 시장 성장을 촉진할 것으로 예상됩니다. 2024년 1월, 미국 FDA는 피부암 탐지용 AI 의료기기 'DermaSensor'를 최초로 승인했습니다.

종양학에서의 AI 적용은 조기발견, 정밀의료, 맞춤형 치료 계획 등 획기적인 진전을 이룩하고 있습니다. 방대한 데이터세트 분석, 미묘한 패턴 식별, 실시간 인사이트 제공 등 AI의 능력은 암 진단과 치료에 혁명을 일으키고, 환자 예후 개선과 의료 서비스 제공의 효율성을 높이는 새로운 시대를 열 수 있는 잠재력을 가지고 있습니다.

The global AI in oncology market size was estimated at USD 6.00 billion in 2025 and is expected to reach USD 38.91 billion by 2033, growing at a CAGR of 24.77% from 2026 to 2033. The growth of the market is attributed to increasing prevalence of cancer, technological advancement in cancer diagnostics & healthcare infrastructure, and an increasing demand for early detection and classification of cancer.

In addition, rising adoption of precision medicine is drives market growth further. The increasing incidence of cancer globally has led to a growing dependence on AI in the field of oncology. According to the NIH estimates of 2023, approximately 2.0 million individuals in the U.S. are diagnosed with cancer. Breast cancer was the most diagnosed cancer, with an estimated 297,790 cases in women and 2,800 cases in men. Among men, prostate cancer was the most frequently diagnosed cancer, and overall, it was the second most common diagnosis, with an anticipated 288,300 cases. The estimated number of new cases of lung and bronchus cancer made it the third most diagnosed cancer.

The growing initiatives undertaken by public and private organizations to invest in research and development (R&D) for introduction of novel technologies are further anticipated to fuel growth of the market. For instance, in October 2022, Tempus, a company specializing in precision medicine and AI, recently announced a program called Tempus+. This proprietary program utilizes real-world data to power collaborative precision oncology research. A community of researchers, including Baylor College of Medicine, Allegheny Health Network, Stanford Cancer Center, Rush University Medical Center, TriHealth, and others, is already using the Tempus+ program to advance their research. Furthermore, increasing product approval of AI-associated medical devices is anticipated to boost market growth. In January 2024, the U.S. FDA approved the first AI medical device, DermaSensor, to detect skin cancer.

The future of AI applications in cancer care is poised for groundbreaking advancements, encompassing early detection, precision medicine, and personalized treatment plans. AI's ability to analyze vast datasets, identify subtle patterns, and provide real-time insights holds the potential to revolutionize cancer diagnosis and therapy, ushering in a new era of improved patient outcomes and more efficient healthcare delivery.

Global AI In Oncology Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global AI in oncology market report based on component type, cancer type, application, end use, and region:

Component Type Outlook (Revenue, USD Million, 2021 - 2033)
Software Solutions
Hardware
Services
Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Diagnostics (Pathology, Cancer Radiology)
Radiation therapy (Radiotherapy)
Research & Development (Drug design, development process, etc.)
Chemotherapy
Immunotherapy
End Use Type Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Surgical Centers & Medical Institutes
Others (Pharmaceutical companies, Research institutes & training centers)
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1 Market Segmentation and Scope
- 1.1.1 Segment scope
- 1.1.2 Regional scope
- 1.1.3 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased database:
- 1.3.2 GVR's internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
1.4 Information or Data Analysis
- 1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity Flow Analysis
  - 1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations

Chapter 2. Executive Summary

2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights

Chapter 3. AI In Oncology Market Variables, Trends, & Scope

3.1 Market Lineage Outlook
- 3.1.1 Parent market sanalysis
3.2 Market Dynamics
- 3.2.1 Market drivers analysis
- 3.2.2 Market restraint analysis
- 3.2.3 Market opportunity analysis
- 3.2.4 Market challenges analysis
3.3 AI In Oncology: Market Analysis Tools
- 3.3.1 Industry analysis - Porter's Five Forces Analysis
- 3.3.2 PESTLE analysis
3.4 Case studies

Chapter 4. AI In Oncology Market Segment Analysis, By Component Type, 2021 - 2033 (USD Million)

4.1 Definition and Scope
4.2 Component Type Market Share Analysis, 2025 & 2033
4.3 Segment Dashboard
4.4 Global AI In Oncology Market, by Component, 2021 to 2033
4.5 Software Solutions
- 4.5.1 Software solutions market estimates and forecast, 2021 - 2033 (USD Million)
4.6 Hardware
- 4.6.1 Hardware market estimates and forecast, 2021 - 2033 (USD Million)
4.7 Services
- 4.7.1 Services market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 5. AI In Oncology Market Segment Analysis, By Cancer Type, 2021 - 2033 (USD Million)

5.1 Definition and Scope
5.2 Cancer Type Market Share Analysis, 2025 & 2033
5.3 Segment Dashboard
5.4 Global AI In Oncology Market, by Cancer Type, 2021 to 2033
5.5 Breast Cancer
- 5.5.1 Breast cancer market estimates and forecast, 2021 - 2033 (USD Million)
5.6 Lung Cancer
- 5.6.1 Lung cancer market estimates and forecast, 2021 - 2033 (USD Million)
5.7 Prostate Cancer
- 5.7.1 Prostate cancer market estimates and forecast, 2021 - 2033 (USD Million)
5.8 Colorectal Cancer
- 5.8.1 Colorectal cancer market estimates and forecast, 2021 - 2033 (USD Million)
5.9 Brain Tumor
- 5.9.1 Brain tumor market estimates and forecast, 2021 - 2033 (USD Million)
5.10 Others
- 5.10.1 Others market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 6. AI In Oncology Market Segment Analysis, By Application, 2021 - 2033 (USD Million)

6.1 Definition and Scope
6.2 Application Market Share Analysis, 2025 & 2033
6.3 Segment Dashboard
6.4 Global AI In Oncology Market, by Application, 2021 to 2033
6.5 Diagnostics (Pathology, Cancer Radiology)
- 6.5.1 Diagnostics (pathology, cancer radiology) market estimates and forecast, 2021 - 2033 (USD Million)
6.6 Radiation Therapy (Radiotherapy)
- 6.6.1 Radiation therapy (radiotherapy) market estimates and forecast, 2021 - 2033 (USD Million)
6.7 Research & Development (Drug Design, Development Process, etc.)
- 6.7.1 Research & development (drug design, development process, etc.) market estimates and forecast, 2021 - 2033 (USD Million)
6.8 Chemotherapy
- 6.8.1 Chemotherapy market estimates and forecast, 2021 - 2033 (USD Million)
6.9 Immunotherapy
- 6.8.1 Immunotherapy market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 7. AI In Oncology Market Segment Analysis, By End Use Type, 2021 - 2033 (USD Million)

7.1 Definition and Scope
7.2 Application Market Share Analysis, 2025 & 2033
7.3 Segment Dashboard
7.4 Global AI In Oncology Market, by Application, 2021 to 2033
7.5 Hospitals
- 7.5.1 Hospitals market estimates and forecast, 2021 - 2033 (USD Million)
7.6 Surgical Centers & Medical Institutes
- 7.6.1 Surgical centers & medical institutes market estimates and forecast, 2021 - 2033 (USD Million)
7.7 Others (Pharmaceutical Companies, Research Institutes & Training Centers)
- 7.7.1 Others (pharmaceutical companies, research institutes & training centers) market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. AI In Oncology Market Segment Analysis, By Region, By Component, By Cancer Type, By Application, By End-use, 2021 - 2033 (USD Million)

8.1. Definition & Scope
8.2. Regional Market Share Analysis, 2025 & 2033
8.3. Regional Market Dashboard
8.4. Regional Market Snapshot
8.5. SWOT Analysis
8.6. North America
- 8.6.1. North America Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.6.2. U.S.
  - 8.6.2.1. Key Country Dynamic
  - 8.6.2.2. Regulatory Framework
  - 8.6.2.3. Competitive Insights
  - 8.6.2.4. U.S. Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.6.3. Canada
  - 8.6.3.1. Key Country Dynamic
  - 8.6.3.2. Regulatory Framework
  - 8.6.3.3. Competitive Insights
  - 8.6.3.4. Canada Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
8.7. Europe
- 8.7.1. Europe Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.2. Germany
  - 8.7.2.1. Key Country Dynamic
  - 8.7.2.2. Regulatory Framework
  - 8.7.2.3. Competitive Insights
  - 8.7.2.4. Germany Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.3. UK
  - 8.7.3.1. Key Country Dynamic
  - 8.7.3.2. Regulatory Framework
  - 8.7.3.3. Competitive Insights
  - 8.7.3.4. UK Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.4. France
  - 8.7.4.1. Key Country Dynamic
  - 8.7.4.2. Regulatory Framework
  - 8.7.4.3. Competitive Insights
  - 8.7.4.4. France Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.5. Italy
  - 8.7.5.1. Key Country Dynamic
  - 8.7.5.2. Regulatory Framework
  - 8.7.5.3. Competitive Insights
  - 8.7.5.4. Italy Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.6. Spain
  - 8.7.6.1. Key Country Dynamic
  - 8.7.6.2. Regulatory Framework
  - 8.7.6.3. Competitive Insights
  - 8.7.6.4. Spain Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.7. Denmark
  - 8.7.7.1. Key Country Dynamic
  - 8.7.7.2. Regulatory Framework
  - 8.7.7.3. Competitive Insights
  - 8.7.7.4. Denmark Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.8. Sweden
  - 8.7.8.1. Key Country Dynamic
  - 8.7.8.2. Regulatory Framework
  - 8.7.8.3. Competitive Insights
  - 8.7.8.4. Sweden Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.7.9. Norway
  - 8.7.9.1. Key Country Dynamic
  - 8.7.9.2. Regulatory Framework
  - 8.7.9.3. Competitive Insights
  - 8.7.9.4. Norway Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
8.8. Asia Pacific
- 8.8.1. Asia Pacific Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.2. Japan
  - 8.8.2.1. Key Country Dynamic
  - 8.8.2.2. Regulatory Framework
  - 8.8.2.3. Competitive Insights
  - 8.8.2.4. Japan Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.3. China
  - 8.8.3.1. Key Country Dynamic
  - 8.8.3.2. Regulatory Framework
  - 8.8.3.3. Competitive Insights
  - 8.8.3.4. China Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.4. India
  - 8.8.4.1. Key Country Dynamic
  - 8.8.4.2. Regulatory Framework
  - 8.8.4.3. Competitive Insights
  - 8.8.4.4. India Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.5. South Korea
  - 8.8.5.1. Key Country Dynamic
  - 8.8.5.2. Regulatory Framework
  - 8.8.5.3. Competitive Insights
  - 8.8.5.4. South Korea Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.6. Australia
  - 8.8.6.1. Key Country Dynamic
  - 8.8.6.2. Regulatory Framework
  - 8.8.6.3. Competitive Insights
  - 8.8.6.4. Australia Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.8.7. Thailand
  - 8.8.7.1. Key Country Dynamic
  - 8.8.7.2. Regulatory Framework
  - 8.8.7.3. Competitive Insights
  - 8.8.7.4. Thailand Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
8.9. Latin America
- 8.9.1. Latin America Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9.2. Brazil
  - 8.9.2.1. Key Country Dynamic
  - 8.9.2.2. Regulatory Framework
  - 8.9.2.3. Competitive Insights
  - 8.9.2.4. Brazil Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9.3. Mexico
  - 8.9.3.1. Key Country Dynamic
  - 8.9.3.2. Regulatory Framework
  - 8.9.3.3. Competitive Insights
  - 8.9.3.4. Mexico Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.9.4. Argentina
  - 8.9.4.1. Key Country Dynamic
  - 8.9.4.2. Regulatory Framework
  - 8.9.4.3. Competitive Insights
  - 8.9.4.4. Argentina Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
8.10. MEA
- 8.10.1. MEA Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.2. South Africa
  - 8.10.2.1. Key Country Dynamic
  - 8.10.2.2. Regulatory Framework
  - 8.10.2.3. Competitive Insights
  - 8.10.2.4. South Africa Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.3. Saudi Arabia
  - 8.10.3.1. Key Country Dynamic
  - 8.10.3.2. Regulatory Framework
  - 8.10.3.3. Competitive Insights
  - 8.10.3.4. Saudi Arabia Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.4. UAE
  - 8.10.4.1. Key Country Dynamic
  - 8.10.4.2. Regulatory Framework
  - 8.10.4.3. Competitive Insights
  - 8.10.4.4. UAE Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)
- 8.10.5. Kuwait
  - 8.10.5.1. Key Country Dynamic
  - 8.10.5.2. Regulatory Framework
  - 8.10.5.3. Competitive Insights
  - 8.10.5.4. Kuwait Healthcare AI in Oncology Market, 2021 - 2033 (USD Million)

Chapter 9. AI In Oncology Market - Competitive Analysis

9.1. Recent Developments & Impact Analysis, by Key Market Participants
9.2. Company Categorization
9.3. Company Profiles
- 9.3.1. Azra AI
  - 9.3.1.1. Overview
  - 9.3.1.2. Financial Performance
  - 9.3.1.3. Service Benchmarking
  - 9.3.1.4. Strategic Initiatives
- 9.3.2. ICAD, INC.
  - 9.3.2.1. Overview
  - 9.3.2.2. Financial Performance
  - 9.3.2.3. Service Benchmarking
  - 9.3.2.4. Strategic Initiatives
- 9.3.3. Siemens Healthcare GmbH
  - 9.3.3.1. Overview
  - 9.3.3.2. Financial Performance
  - 9.3.3.3. Service Benchmarking
  - 9.3.3.4. Strategic Initiatives
- 9.3.4. Intel Corporation
  - 9.3.4.1. Overview
  - 9.3.4.2. Financial Performance
  - 9.3.4.3. Service Benchmarking
  - 9.3.4.4. Strategic Initiatives
- 9.3.5. GE HealthCare
  - 9.3.5.1. Overview
  - 9.3.5.2. Financial Performance
  - 9.3.5.3. Service Benchmarking
  - 9.3.5.4. Strategic Initiatives
- 9.3.6. NVIDIA Corporation
  - 9.3.6.1. Overview
  - 9.3.6.2. Financial Performance
  - 9.3.6.3. Service Benchmarking
  - 9.3.6.4. Strategic Initiatives
- 9.3.7. Digital Diagnostics Inc.
  - 9.3.7.1. Overview
  - 9.3.7.2. Financial Performance
  - 9.3.7.3. Service Benchmarking
  - 9.3.7.4. Strategic Initiatives
- 9.3.8. ConcertAI
  - 9.3.8.1. Overview
  - 9.3.8.2. Financial Performance
  - 9.3.8.3. Service Benchmarking
  - 9.3.8.4. Strategic Initiatives
- 9.3.9. Median Technologies
  - 9.3.9.1. Overview
  - 9.3.9.2. Financial Performance
  - 9.3.9.3. Service Benchmarking
  - 9.3.9.4. Strategic Initiatives
- 9.3.10. PathAI
  - 9.3.10.1. Overview
  - 9.3.10.2. Financial Performance
  - 9.3.10.3. Service Benchmarking
  - 9.3.10.4. Strategic Initiatives
- 9.3.11. MVision AI
  - 9.3.11.1. Overview
  - 9.3.11.2. Financial Performance
  - 9.3.11.3. Service Benchmarking
  - 9.3.11.4. Strategic Initiatives

종양학 분야 AI 시장 규모, 점유율, 동향 분석 보고서 : 구성요소 유형별, 암 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

AI In Oncology Market Size, Share & Trends Analysis Report By Component Type, By Cancer Type, By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033

종양학 분야 AI 시장 개요

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 종양학 분야 AI 시장 변수, 동향, 범위

제4장 종양학 분야 AI 시장, 구성요소 유형별, 2021-2033년

제5장 종양학 분야 AI 시장, 암 유형별, 2021-2033년

제6장 종양학 분야 AI 시장, 용도별, 2021-2033년

제7장 종양학 분야 AI 시장, 최종 용도별, 2021-2033년

제8장 종양학 분야 AI 시장(지역별, 구성요소별, 암 유형별, 용도별, 최종 용도별, 2021-2033년)

제9장 종양학 분야 AI 시장 - 경쟁 분석

AI In Oncology Market Summary

Table of Contents